Kenneth Stauderman Biography and Net Worth

Chief Scientific Officer of CalciMedica

Dr. Stauderman has more than 30 years of pharmaceutical and biotechnology research experience focused on intracellular calcium signaling. A CalciMedica co-founder, he contributed to foundational work identifying STIM1 as a key regulator of CRAC channels.

What is Kenneth A. Stauderman's net worth?: The estimated net worth of Kenneth A. Stauderman is at least $3.86 thousand as of July 28th, 2025. Dr. Stauderman owns 2,588 shares of CalciMedica stock worth more than $3,856 as of October 7th. This net worth evaluation does not reflect any other assets that Dr. Stauderman may own. Learn More about Kenneth A. Stauderman's net worth.
How do I contact Kenneth A. Stauderman?: The corporate mailing address for Dr. Stauderman and other CalciMedica executives is 505 Coast Boulevard South, Suite 307, LA Jolla, CA, 92037. CalciMedica can also be reached via phone at 858-952-5500 and via email at [email protected]. Learn More on Kenneth A. Stauderman's contact information.
Has Kenneth A. Stauderman been buying or selling shares of CalciMedica?: Kenneth A. Stauderman has not been actively trading shares of CalciMedica during the past quarter. Most recently, on Monday, July 28th, Kenneth A. Stauderman bought 200 shares of CalciMedica stock. The stock was acquired at an average cost of $19.80 per share, with a total value of $3,960.00. Following the completion of the transaction, the insider now directly owns 2,588 shares of the company's stock, valued at $51,242.40. Learn More on Kenneth A. Stauderman's trading history.
Who are CalciMedica's active insiders?: CalciMedica's insider roster includes A. Leheny (CEO), Eric Roberts (Insider), and Kenneth Stauderman (Chief Scientific Officer). Learn More on CalciMedica's active insiders.
Are insiders buying or selling shares of CalciMedica?: In the last twelve months, CalciMedica insiders bought shares 1 times. They purchased a total of 49,794 shares worth more than $199,176.00. The most recent insider tranaction occured on June, 25th when Director Fred A Middleton bought 49,794 shares worth more than $199,176.00. Insiders at CalciMedica own 28.3% of the company. Learn More about insider trades at CalciMedica.
Information on this page was last updated on 6/25/2026.

Kenneth A. Stauderman Insider Trading History at CalciMedica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/28/2025	Buy	200	$19.80	$3,960.00	2,588
7/25/2025	Sell	200	$18.25	$3,650.00	2,588
7/1/2025	Buy	200	$9.25	$1,850.00	200

Kenneth A. Stauderman Buying and Selling Activity at CalciMedica

CalciMedica Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $1.47

$1.49

50 Day Range

MA: $2.55

$1.49

$5.00

2 Week Range

Now: $1.47

$1.42

$36.00

Volume

315 shs

Average Volume

187,891 shs

Market Capitalization

$10.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76